本季度信息
2025年第三季度，杭州泰格医药科技股份有限公司实现营业收入17.75亿元，同比增长3.86%。同期经调整净利润（扣除非经常性损益后）为1.15亿元，同比下降54.25%。
财报显示，前三季度经营活动产生的现金流量净额为7.40亿元，同比增长27.78%。在成本结构方面，报告期内销售费用较去年同期有所增长，管理费用则小幅下降，研发投入同比保持增长，体现出公司对项目创新及服务能力升级的持续投入。
本季度信息
2025年第三季度，杭州泰格医药科技股份有限公司实现营业收入17.75亿元，同比增长3.86%。同期经调整净利润（扣除非经常性损益后）为1.15亿元，同比下降54.25%。
财报显示，前三季度经营活动产生的现金流量净额为7.40亿元，同比增长27.78%。在成本结构方面，报告期内销售费用较去年同期有所增长，管理费用则小幅下降，研发投入同比保持增长，体现出公司对项目创新及服务能力升级的持续投入。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.